ISSN: 2579-0811

International Digital Organization for Scientific Research IDOSR JBBAF24/93.252900
IDOSR JOURNAL OF BIOCHEMISTRY, BIOTECHNOLOGY AND ALLIED FIELDS 9(3):25-29, 2024.
https://doi.org/10.59298/IDOSR/JBBAF/24/93.2529000

# Advances and Challenges for the Malaria Vaccine: A Review

**Mugisha Emmanuel K.**

**Faculty of Science and Technology Kampala International University Uganda**

**ABSTRACT**

Malaria remains a leading cause of morbidity and mortality worldwide, particularly in sub-Saharan Africa and Southeast Asia, where transmission rates are highest. Traditional control measures, such as insecticide-treated bed nets and antimalarial drugs, have helped reduce the disease's impact, but challenges such as drug and insecticide resistance continue to undermine these efforts. A highly effective malaria vaccine represents a crucial step towards achieving long-term control and eventual eradication. This review explores recent advances in malaria vaccine development, including the RTS, S/AS01 and R21/Matrix-M vaccines, while highlighting their limitations related to efficacy, immunity duration, and accessibility in resource-poor regions. Additionally, it addresses the challenges in developing multivalent vaccines, targeting different strains of Plasmodium, and the need for integrated approaches combining vaccination with existing control strategies. Looking ahead, the review discusses the potential of next-generation vaccines, mRNA platforms, and hybrid strategies that could enhance global malaria control efforts.

**Keywords:** Malaria vaccine, RTS, S/AS01, R21/Matrix-M, transmission-blocking vaccines, malaria control.

## INTRODUCTION

Malaria remains a persistent and deadly public health issue, particularly in regions like sub-Saharan Africa and Southeast Asia, where transmission rates are highest. The disease is caused by the *Plasmodium* parasites, with *Plasmodium falciparum* being the deadliest strain, and it is spread through the bites of infected *Anopheles* mosquitoes [1]. Despite global efforts to combat the disease, malaria continues to cause millions of cases and hundreds of thousands of deaths annually, with children under five and pregnant women suffering disproportionately due to their heightened vulnerability to severe illness and death.

Traditional malaria control measures, such as the use of insecticide-treated bed nets, indoor residual spraying, and the widespread administration of antimalarial drugs, have led to significant reductions in transmission in many areas [2]. However, these methods have limitations, including the rise of insecticide-resistant mosquito populations and drug-resistant strains of *Plasmodium*. As a result, there has been a strong push toward developing a long-term solution through a highly effective malaria vaccine.

The development of such a vaccine has been a longstanding goal in the fight against malaria, with many candidates being tested over the years [3]. Among the most significant advancements in recent times is the RTS,S/AS01 vaccine, which represents the first and, so far, the most successful vaccine candidate to receive approval for broader use. Despite this progress, the vaccine has shown moderate efficacy, particularly in children, with concerns over its longevity in providing immunity and its accessibility to the most vulnerable populations [4].

This review delves into the scientific and logistical challenges that have hindered the development of more effective malaria vaccines. It also highlights the ongoing efforts in vaccine research, including newer candidates that aim to overcome the limitations of RTS,S/AS01. Additionally, it examines the broader implications of vaccine development for global malaria control, particularly how these advancements can complement existing strategies and what is needed to achieve the goal of malaria eradication [5].

Ultimately, while substantial progress has been made in malaria vaccine research, this review underscores that many hurdles remain before an ideal vaccine—one that provides lasting immunity, is easily accessible, and can be deployed widely—can be realized [6]. The continued pursuit of improved vaccine candidates, alongside strengthened health infrastructure and global cooperation, remains

essential to effectively controlling and eventually eliminating malaria.

### The Need for a Malaria Vaccine

Malaria control efforts have helped reduce the global burden of the disease, but eradication remains elusive. Drug resistance, insecticide resistance in mosquitoes, and challenges in maintaining high coverage of interventions necessitate a more sustainable solution. A vaccine that can provide long-term immunity would be a game-changer in the fight against malaria, potentially reducing transmission and disease severity, especially in regions with high malaria endemicity [7].

The *Plasmodium* parasite presents unique challenges for vaccine development due to its complex life cycle, involving multiple stages within both human and mosquito hosts [8]. This complexity has hindered the development of a highly effective vaccine, as immunity must target different stages of the parasite's life cycle, including the pre-erythrocytic, erythrocytic, and sexual stages.

### Advances in Malaria Vaccine Development

#### 1. *RTS,S/AS01* (Mosquirix)

The *RTS,S/AS01* vaccine, commonly known as Mosquirix, represents the first and most advanced malaria vaccine to reach large-scale clinical trials and subsequent rollout. Developed by GlaxoSmithKline (GSK) in partnership with PATH Malaria Vaccine Initiative and the World Health Organization (WHO), Mosquirix targets the pre-erythrocytic stage of *Plasmodium falciparum*, the deadliest malaria parasite [9].

**Efficacy:** Clinical trials demonstrated that *RTS,S* provides partial protection against malaria in children. The vaccine's efficacy was found to be around 30–50% in reducing clinical malaria cases in children aged 5–17 months after a series of four doses, with the efficacy decreasing over time.

**Pilot Program:** In 2019, the WHO initiated large-scale pilot immunization programs in three African countries — Malawi, Ghana, and Kenya. The vaccine is delivered through the Expanded Program on Immunization (EPI), targeting children under two years of age.

**Challenges:** While Mosquirix marks a significant breakthrough, its relatively low efficacy compared to other vaccines and the need for a multi-dose regimen are notable challenges. Long-term immunity is also a concern, with immunity waning after the first-year post-vaccination [10].

#### 2. *R21/Matrix-M* Vaccine

Another promising vaccine in the pipeline is the *R21/Matrix-M* vaccine, developed by the University of Oxford and the Serum Institute of India [11]. Like Mosquirix, this vaccine targets the circumsporozoite protein (CSP) of *Plasmodium falciparum* during its pre-erythrocytic stage.

**Efficacy:** Early trials of *R21* have shown higher efficacy than *RTS,S*, with Phase 2 trials reporting up to 77% efficacy against clinical malaria. The vaccine has undergone Phase 3 clinical trials, and results are highly anticipated.

**Dosing and Stability:** The *R21* vaccine shows promise in offering higher efficacy with fewer doses, potentially addressing the challenge of long-term immunity. It also appears to be more stable and easier to administer, which could enhance its scalability in low-resource settings [12].

#### 3. Transmission-Blocking Vaccines (TBVs)

Transmission-blocking vaccines aim to prevent the parasite from developing within the mosquito after a human is bitten, thereby halting the transmission cycle.

**PfSPZ Vaccine:** Developed by Sanaria Inc., the *PfSPZ* vaccine uses weakened *Plasmodium falciparum* sporozoites to induce immunity. It targets both pre-erythrocytic and transmission stages, offering potential for long-lasting protection [13]. Early-stage trials have shown promising results in terms of safety and immune response.

**Challenges:** TBVs must demonstrate that they can effectively block transmission at the population level. Achieving widespread coverage in endemic areas will be critical for their success.

### Challenges in Malaria Vaccine Development

#### Efficacy and Longevity

The relatively modest efficacy of current malaria vaccines compared to vaccines for other diseases, such as measles or polio, remains a key challenge. Current vaccines provide partial protection and require multiple doses over an extended period, which can be logistically challenging in low-resource settings. Maintaining high coverage and follow-up for booster doses can be difficult, particularly in rural areas [14].

Moreover, the waning immunity observed with Mosquirix has raised concerns about the long-term effectiveness of malaria vaccines. Researchers are exploring ways to extend the duration of protection through booster doses, alternative formulations, or combinations with other interventions [15].

#### Targeting Multiple Malaria Parasite Strains

While much of the focus has been on *Plasmodium falciparum*, other malaria parasites, such as *Plasmodium vivax*, also cause significant disease burden, especially in regions of South Asia and Latin America. Developing a vaccine that can target multiple strains of malaria is challenging due to genetic variability among the different species.

Efforts are underway to create multivalent vaccines that can offer broad-spectrum protection, but these are still in the early stages of development. Achieving protection against diverse strains of malaria will require a deeper understanding of parasite biology and immune responses [15].

### Drug and Insecticide Resistance

The growing resistance to antimalarial drugs and insecticides among malaria parasites and vectors poses an additional hurdle. Malaria vaccines will need to complement existing tools, such as bed nets and antimalarial medications, which are increasingly losing effectiveness due to resistance. Vaccines that target parasite transmission stages offer hope in mitigating this challenge, as they reduce the likelihood of resistance by cutting off the parasite's life cycle [16-19].

### Vaccine Accessibility and Equity

A major challenge for malaria vaccination in endemic regions is ensuring equitable access to vaccines, particularly in remote and resource-limited areas. The cost of vaccine development, production, and distribution can be prohibitive, especially when targeting low-income populations. Public-private partnerships and funding from global health organizations, such as Gavi and the WHO, are crucial in ensuring that vaccines reach the most vulnerable populations.

Another issue is vaccine acceptance, as misinformation and cultural beliefs may prevent some communities from embracing vaccination campaigns [8]. Education and community engagement will be essential in overcoming vaccine hesitancy.

### Integration with Other Malaria Control Measures

The success of a malaria vaccine will depend on how well it integrates with existing malaria control strategies, such as the use of insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs. Vaccines should be viewed as part of a broader toolkit to reduce malaria transmission, not as a standalone solution. Integrated approaches that combine vaccination with improved surveillance, vector control, and healthcare delivery systems will be critical for maximizing the impact of vaccines [11].

### Future Directions for Malaria Vaccines

**Next-Generation Vaccines:** Researchers are working on next-generation vaccines that can overcome the limitations of current candidates. This includes developing multivalent vaccines that target multiple stages of the parasite's life cycle and multiple strains of the parasite. New adjuvants and delivery platforms are also being explored to enhance vaccine efficacy and longevity.

**mRNA Vaccines:** The success of mRNA technology in the rapid development of COVID-19 vaccines has sparked interest in using similar platforms for malaria. mRNA-based vaccines could allow for more precise targeting of *Plasmodium* antigens and could be rapidly updated to address emerging strains [20-22].

**Hybrid Strategies:** Combining malaria vaccines with other control measures, such as gene-drive technology to eliminate mosquito populations, or integrating vaccines with chemoprevention strategies, offers a promising path forward. Such hybrid strategies could accelerate progress toward malaria elimination.

## CONCLUSION

Malaria remains a formidable public health challenge, particularly in sub-Saharan Africa and Southeast Asia, where the disease continues to claim lives despite significant advancements in control measures. Traditional interventions like insecticide-treated nets, indoor residual spraying, and antimalarial drugs have contributed to reducing transmission. However, the emergence of insecticide and drug resistance, coupled with the complexity of the *Plasmodium* parasite's life cycle, underscores the need for a more sustainable and long-term solution—a highly effective vaccine. Recent progress in vaccine development, notably with the RTS,S/AS01 and the R21/Matrix-M vaccines, offers hope. However, these vaccines face limitations related to efficacy, duration of immunity, and accessibility in resource-limited settings. The challenges of developing vaccines targeting multiple strains of *Plasmodium*, ensuring widespread access, and integrating vaccines with other malaria control strategies remain substantial.

## RECOMMENDATIONS

**Enhancing Vaccine Efficacy and Longevity:** Ongoing research should focus on improving the efficacy and longevity of malaria vaccines. Future vaccine candidates should aim for multistage and multistrain protection to address the genetic diversity of *Plasmodium* species. Exploring novel vaccine platforms, such as mRNA technology, could potentially offer more robust and durable immunity.

**Boosting Accessibility and Equity:** Global health organizations, governments, and private sectors must collaborate to ensure that vaccines are affordable and accessible, especially to the most vulnerable populations in malaria-endemic regions. Funding mechanisms, such as Gavi's support for vaccine procurement, must be strengthened to guarantee equitable distribution. Community engagement and education programs are essential to overcoming vaccine hesitancy and ensuring high uptake.

**Combining Vaccination with Existing Strategies:** Malaria vaccines should not be seen as a standalone solution but as part of an integrated approach to malaria control. Combining vaccination with effective vector control, chemoprevention, and

improved healthcare infrastructure can create a synergistic effect that maximizes the impact on malaria transmission.

**Pursuing Hybrid Strategies:** Innovative hybrid strategies, such as gene-drive technology to reduce mosquito populations and vaccines combined with drug-based prevention, should be further explored. Such combined approaches could accelerate progress toward malaria elimination.

**Strengthening Global Partnerships:** Continued international collaboration is critical for advancing malaria vaccine research and development. Partnerships between research institutions, pharmaceutical companies, governments, and non-governmental organizations will play a key role in developing next-generation vaccines and ensuring they are available to those who need them most. By addressing these challenges and leveraging innovative solutions, the global community can move closer to realizing the ultimate goal of malaria eradication.

## REFERENCES


1. Laurens, M. B. (2020). RTS,S/AS01 vaccine (Mosquirix™): an overview. Human Vaccines & Immunotherapeutics, 16(3), 480-489. https://doi.org/10.1080/21645515.2019.1669415
2. Datoo, M. S., Natama, M. H., Somé, A., et al. (2021). Efficacy of a low-dose candidate malaria vaccine, R21, in children in Burkina Faso: a randomised, controlled, double-blind phase 2b trial. The Lancet, 397(10287),1809-1818. https://doi.org/10.1016/S0140-6736(21)00943-0
3. Draper, S. J., Sack, B. K., King, C. R., et al. (2018). Malaria vaccines: recent advances and new horizons. Cell Host & Microbe, 24(1),43-56. https://doi.org/10.1016/j.chom.2018.06.008
4. World Health Organization (WHO). (2021). WHO recommends groundbreaking malaria vaccine for children at risk. https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk
5. Sissoko, M. S., Dicko, A., Toure, O., et al. (2017). Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. The Lancet Infectious Diseases, 17(5), 498-509. https://doi.org/10.1016/S1473-3099(17)30104-4
6. Mordmüller, B., Surat, G., Lagler, H., et al. (2017). Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature, 542(7642), 445-449. https://doi.org/10.1038/nature21060
7. Aly, A. S. I., & Vaughan, A. M. (2022). Advances in malaria vaccines: pre-erythrocytic and transmission-blocking approaches. Frontiers in Immunology, 13, 871511. https://doi.org/10.3389/fimmu.2022.871511
8. Alonso, P., & Brown, G. (2021). Challenges in malaria vaccine research and development. Annual Review of Medicine, 72, 355-370. https://doi.org/10.1146/annurev-med-090419-092826
9. Healy, S. A., Anderson, C., Swihart, B. J., et al. (2021). Preclinical and clinical development of Plasmodium falciparum sporozoite vaccines. Frontiers in Immunology, 12, 775970. https://doi.org/10.3389/fimmu.2021.775970
10. Sumner, T., Hetzel, M. W., Molineaux, L., et al. (2022). The RTS,S malaria vaccine: how much will it reduce malaria burden? NPJ Vaccines, 7(1), 62. https://doi.org/10.1038/s41541-022-00517-y
11. Ekpono, E. U., Aja, P. M., Ibiam, U. A., Alum, E. U., &Ekpono, U. E. Ethanol Root-extract of Sphenocentrumjollyanum Restored Altered Haematological Markers in Plasmodium berghei-infected Mice. Earthline Journal of Chemical Sciences. 2019; 2(2): 189-203. https://doi.org/10.34198/ejcs.2219.189203 .
12. Egwu, C. O., Aloke, C., Chukwu, J., Agwu, A., Alum, E.,Tsamesidis, I, et al. A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 2022 Dec;22(4):627-640. doi: 10.4314/ahs.v22i4.68.
13. Egwu, C.O., Aloke, C., Chukwu, J., Nwankwo, J.C., Irem, C., Nwagu, K.E., Nwite, F., Agwu, A.O., Alum, E., Offor, C.E. and Obasi, N.A. Assessment of the Antimalarial Treatment Failure in Ebonyi State, Southeast Nigeria. J Xenobiot. 2023 Jan3;13(1):16-26.doi: 10.3390/jox13010003.
14. Kungu, E., Inyangat, R., Ugwu, O.P.C. and Alum, E. U. (2023). Exploration of

Medicinal Plants Used in the Management of Malaria in Uganda. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(1):101-108.https://nijournals.org/wp-content/uploads/2023/10/NIJRMS-41101-108-2023.docx.pdf

15. Obeagu, E. I., Alum, E. U. and Ugwu, O. P. C. Hepcidin's Antimalarial Arsenal: Safeguarding the Host. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY. 2023;4(2):1-8. https://doi.org/10.59298/NIJPP/2023/10.1.1100
16. Obeagu, E. I., Alum, E. U. and Ugwu, O. P. C. Hepcidin: The Gatekeeper of Iron in Malaria Resistance NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. 2023;4(2):1-8. https://doi.org/10.59298/NIJRMS/2023/10.1.1400
17. Alum, E, U., Ugwu O, P, C., Egba S, I., Uti D, E., Alum, B, N., (2024). Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research 11(2):16-22. https://doi.org/10.59298/INOSRSR/2024/1.1.21622
18. Okechukwu PC Ugwu, Okwesili FC Nwodo, Parker E Joshua, Christian E Odo, Abubakar Bawa, EC Ossai, CC Adonu (2013). Anti-malaria and hematological analyses of ethanol leaf extract of Moringa oleifera on malaria infected mice *International Journal of Pharmacy and Biological Science 3(1) 360-371.*
19. Okechukwu PC Ugwu, OFC Nwodo, PE Joshua, CE Odo, EC Ossai, B Aburbakar(2013). Ameliorative effects of ethanol leaf extract of *Moringa oleifera* on the liver and kidney markers of malaria infected mice. *2(2) 43-52.*
20. Okechukwu PC Ugwu, Okwesili FC Nwodo, Parker E Joshua, Christian E Odo, Emmanuel C Ossai (2013). The effect of ethanol leaf extract of *Moringa oleifera* on the lipid profile of malaria infected mice *Journal of applied science 4(1) 1324-1332.*
21. Enechi OC, CC Okpe, GN Ibe, KO Omeje, PC Ugwu Okechukwu(2016). Effect of Buchholzia coriacea methanol extract on haematological indices and liver function parameters in Plasmodium berghei-infected mice Global Veterinaria 16(1) 57-66.
22. Okechukwu Paul-Chima Ugwu (2011). Anti-Malaria Effect of Ethanol Extract of Moringa Oleifera (Agbaji) Leaves on Malaria Induced Mice. *University of Nigeria Nsukka, 39.*

**CITE AS: Mugisha Emmanuel K. (2024). Advances and Challenges for the Malaria Vaccine: A Review. IDOSR JOURNAL OF BIOCHEMISTRY, BIOTECHNOLOGY AND ALLIED FIELDS 9(3):25-29. https://doi.org/10.59298/IDOSR/JBBAF/24/93.2529000**